Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337). (Q41119034)
Jump to navigation
Jump to search
scientific article published on 7 July 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337). |
scientific article published on 7 July 2015 |
Statements
1 reference
Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337). (English)
1 reference
Raphael Gottardo
1 reference
Gregory N Dietsch
1 reference
Tressa D Randall
1 reference
Donald W Northfelt
1 reference
Ramesh K Ramanathan
1 reference
Peter A Cohen
1 reference
Kristi L Manjarrez
1 reference
Mona Newkirk
1 reference
James Kyle Bryan
1 reference
Robert M Hershberg
1 reference
7 July 2015
1 reference
1 reference
21
1 reference
24
1 reference
5445-5452
1 reference
Identifiers
1 reference
1 reference